Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Lenalidomide in Large B-cell lymphoma: NCT07240194 Clinical Landscape Report 2026
18 September 2026
NCT07240194 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MDX-2003 in High grade B-cell lymphoma: NCT07249905 Clinical Landscape Report 2026
18 September 2026
NCT07249905 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Envafolimab in Locally Advanced Soft Tissue Sarcoma: NCT07243626 Clinical Landscape Report 2026
18 September 2026
NCT07243626 clinical landscape for Locally Advanced Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
ST-1898 in Hepatocellular Carcinoma: NCT07252661 Clinical Landscape Report 2026
18 September 2026
NCT07252661 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SHR-4610 in Advanced Renal Cell Carcinoma: NCT07239596 Clinical Landscape Report 2026
18 September 2026
NCT07239596 clinical landscape for Advanced Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in PD-L1 positive Triple Negative Breast Cancer: NCT07244874 Clinical Landscape Report 2026
18 September 2026
NCT07244874 clinical landscape for PD-L1 positive Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Envafolimab in Liver metastases: NCT07256223 Clinical Landscape Report 2026
18 September 2026
NCT07256223 clinical landscape for Liver metastases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axicabtagene Ciloleucel in Mediastinal large B-cell lymphoma: NCT07254754 Clinical Landscape Report 2026
18 September 2026
NCT07254754 clinical landscape for Mediastinal large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Lisaftoclax in Diffuse large B-cell lymphoma refractory: NCT07255963 Clinical Landscape Report 2026
18 September 2026
NCT07255963 clinical landscape for Diffuse large B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Eribulin mesylate in Triple Negative Breast Cancer: NCT07255612 Clinical Landscape Report 2026
18 September 2026
NCT07255612 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BAFF-R Chimeric Antigen Receptor T(Hebei Taihe Chunyu Biotechnology) in Mantle-Cell Lymphoma: NCT07259070 Clinical Landscape Report 2026
18 September 2026
NCT07259070 clinical landscape for Mantle-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tagitanlimab in PD-L1 positive Triple Negative Breast Cancer: NCT07258108 Clinical Landscape Report 2026
18 September 2026
NCT07258108 clinical landscape for PD-L1 positive Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…